TABLE 1.

Absorption and Safety With Sustained Use of RELiZORB Evaluation study demographics and baseline characteristics (ITT population)

Parameter	ITT population (n = 39)
Age, y
Mean (SD)	13.8 (5.4)
Min, Max	5, 33
Age category, y
≤12	17 (43.6%)
13–18	17 (43.6%)
≥19	5 (12.8%)
Gender
Male/female	24 (61.5%)/15 (38.5%)
Weight, kg
Mean (SD)	40.83 (12.3)
Height, cm
Mean (SD)	149.84 (18.9)
BMI, kg/m2
Mean (SD)	17.68 (1.8)
CFRD category
CFRD	9 (23.1%)
Non-CFRD	30 (76.9%)

BMI = body mass index; CFRD = cystic fibrosis-related diabetes; ITT = intent-to-treat.